Onconova Therapeutics to Host Analyst Event in New York

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Onconova Therapeutics to Host Analyst Event in New York City on December 19th

NEWTOWN, Pa., Dec. 13, 2013 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX ) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, will be hosting an investor and analyst event on Thursday, December 19, 2013, from 8:00 am to 12:00 pm ET in New York, NY. The meeting will focus on the treatment landscape of myelodysplastic syndromes (MDS) and the development of Onconova's most advanced product candidate, rigosertib, as a novel treatment for MDS and other cancers. The event will feature presentations by leading experts in the fields of oncology and hematology and Onconova management.

Experts will include:

  • Jerome Groopman, M.D., the Dina and Raphael Recanati Chair of Medicine at Harvard Medical School and Chief of Experimental Medicine at Beth Israel Deaconess Medical Center
     
  • James F. Holland, M.D., Distinguished Professor of Neoplastic Diseases at the Icahn School of Medicine at Mount Sinai; Lasker Award winner for contributions to the cure of childhood leukemias
     
  • Jimmie C. Holland, M.D., Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan-Kettering Cancer Center; pioneer in assessing quality of life measures in clinical trials
     
  • Azra Raza, M.D., Director of the MDS Center at Columbia University
     
  • E. Premkumar Reddy, Ph.D., Professor of Oncological Sciences and Structural and Chemical Biology at the Icahn School of Medicine at Mount Sinai; Scientific Founder of Onconova
     
  • Lewis R. Silverman, M.D., Associate Professor Medicine, Hematology and Medical Oncology and Assistant Professor Oncological Sciences at the Icahn School of Medicine at Mount Sinai
     
  • Alan Williamson, Ph.D., Chairman of the Onconova Therapeutics Clinical Advisory Board

The event is open to members of the professional investment community. For more information on attending please contact Michaela Parnell at mparnell@macbiocom.com .

The event audio and slide presentation will be webcast live on the Company's website, www.onconova.com , on the Events & Presentations page under the Investors and Media tab.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are in clinical trials, and several candidates are in pre-clinical stages. For more information, please visit  http://www.onconova.com .

Onconova Therapeutics Benjamin Hoffman, 267-759-3680 or Media: MacDougall Biomedical Communications Chris Erdman, 781-235-3060

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Microtubule Defects Revealed: Impacts on Cancer Treatment

Updated Category News Views 4

Peering into the Heart of Microtubules Ever squint at a tapestry, only to find a rogue thread ruining the pattern? Well, that’s somewhat what scientists at Kanazawa University have found with microtubules, those tiny rods in our cells that usually keep it all together. Using some pretty fancy tech called high-speed atomic force microscopy, these folks peered into the...

Continue Reading
Gillis Joins McGinnis Lochridge as COO Amid Firm's Milestone

Updated Category News Views 1

An Experienced Executor at the Helm Now, here's a story that rings of continuity meeting change. McGinnis Lochridge, a staple of the Texas legal scene since 1927, has tapped Charles Gillis to take charge as their Chief Operating Officer. You'd think they're gearing up to celebrate a hundred years by shaking things up internally. Why not bring in someone seasoned, I say?...

Continue Reading
Low GWP Refrigerants: Potential $13B Market by 2031

Updated Category News Views 2

Refrigerants: They're Hot in More Ways Than One Who would've thought refrigerants could be such a big deal? But here we are. The low global warming potential (GWP) refrigerants market is heating up, projected to jump from $8.17 billion in 2026 to a whopping $13.06 billion by 2031. That's a solid 9.8% CAGR if you're keeping score. The drivers? Well, we’ve got...

Continue Reading
Denver Arts Week: A Cultural Extravaganza Returns

Updated Category News Views 6

Denver's got its art game on again, folks—a sprawling fiesta for the senses called Denver Arts Week is making its return from November 6 to 15. Pack your bags, grab a parka, or whatever you need to brace the Colorado chill, as this ain't just any regular art crawl—it's a full-blown celebration with nearly 300 events jam-packed across the city. If you blink, Denver...

Continue Reading
Expert Vet Advice: When Pet Surgery Is Necessary

Updated Category News Views 4

Tough Calls: Knowing When Your Pet Needs Surgery Alright, when it comes to our furry companions, knowing when to opt for surgery ain't no walk in the park. It's a tricky balance, folks. Is that lump something to worry about? Will that limp heal on its own? HelloNation's recent piece dives into these questions, leveraging the expertise of Veterinarian Lorrie Riggs from...

Continue Reading
James Cahill's Centenary: Honoring a Chinese Art Pioneer

Updated Category News Views 3

A Celebration of a Visionary in Chinese Art In the typically bustling city of Hangzhou, a quiet reverence fell at the China Academy of Art (CAA) on October 17–18, 2026. There, they marked the centenary of one of the titans of art history, James Francis Cahill. He was the kind of person who could walk into a room and change how you looked at the walls. His legacy...

Continue Reading
Littleton U-Pull-It Kicks off New Era with a Bang

Updated Category News Views 3

A Fresh Chapter for Littleton U-Pull-It There's nothing quite like the thrill of a new beginning, especially when it promises to shake up the local business scene. Littleton U-Pull-It, under new ownership, seems to be gearing up for exactly that. They're setting the stage with a grand opening event on October 24. When old hands in the business world like me see moves like...

Continue Reading
Ford Foundation's New Strategy Tackles Global Democracy

Updated Category News Views 4

New Directions in a Changing World Standing at a crossroads of geopolitical upheaval and global uncertainty, the Ford Foundation is shaking things up with a fresh playbook aimed squarely at bolstering democracy across the globe. On October 22, 2026, they rolled out a game plan that's all about reinforcing the backbone of democratic values, essential freedoms, and...

Continue Reading
Clarivate Taps Global Appetite for AI Research Tools

Updated Category News Views 8

A Growing Global Thirst for AI-Enhanced Research It looks like the folks at Clarivate have struck a chord. Their Web of Science Research Intelligence platform is garnering attention across the globe, embraced by more than 100 institutions spanning 25 countries. When you craft something that taps into a core need, well, people will jump on it—and that's exactly what's...

Continue Reading
Direct Digital's Bold Exit: Delists from Nasdaq

Updated Category News Views 5

Delisting Drama: Navigating Direct Digital's Market Move Looks like Direct Digital Holdings is getting caught up in the whirlwind of delisting and deregistering its Class A common stock from the Nasdaq. This move isn't just about hopping off a big exchange—it’s a whole new set of dance steps in the market. Timing and Mechanics of the Departure They’ve set their...

Continue Reading

Top 5 Most Recently Viewed Articles

Costco’s Earnings Anticipation Boosts Market Interest

Updated Category News Views 138

Costco’s Earnings Anticipation Boosts Market Interest Costco Wholesale Corporation (NASDAQ: COST) is generating significant buzz as it heads into its fourth-quarter earnings report, which is set to unveil crucial financial insights. Analysts are eagerly awaiting the results, with many predicting strong performance metrics. What to Expect from the Upcoming Earnings...

Continue Reading
Clara Feldman's Leadership Role at Blank Rome Unveiled

Updated Category News Views 384

Clara Feldman Joins Blank Rome's Luxury Brands Practice Blank Rome LLP is excited to welcome Clara Feldman as the chair of its newly established Luxury Brands practice in New York. This initiative brings together a talented team of attorneys dedicated to providing sophisticated legal expertise to high-end brands. Clara, with her extensive background, is set to enhance the...

Continue Reading
A Paradise Acquisition Corp. Separates Trading of Shares Soon

Updated Category News Views 109

Overview of A Paradise Acquisition Corp. A Paradise Acquisition Corp. (NASDAQ: APADU) is a special purpose acquisition company (SPAC) designed primarily for merging with businesses. Its mission is to initiate mergers or other business combinations, specifically in the leisure and entertainment sectors. Upcoming Trading Changes Starting soon, holders of units sold during...

Continue Reading
Treatment.com AI Inc. Completes Successful Private Placement

Updated Category News Views 244

Treatment.com AI Inc. Completes Successful Private Placement Recently, Treatment.com AI Inc. (CSE: TRUE; OTC: TREIF; FFA: 939) shared exciting news about a significant milestone in its funding journey. The company has successfully closed an over-subscribed non-brokered private placement of special warrants and units, totaling an impressive $1,954,074. This move comes on...

Continue Reading
Atossa Therapeutics Announces Promising Results from Endoxifen Study

Updated Category News Views 31

Atossa Therapeutics Unveils Positive Results from KARISMA-Endoxifen Trial (Z)-Endoxifen has been shown to significantly reduce mammographic breast density, potentially leading to groundbreaking strategies for cancer prevention. Atossa Therapeutics, Inc. (Nasdaq: ATOS), a biopharmaceutical company operating in the clinical stage with a dedication to developing innovative...

Continue Reading